ODG
AVIR icon

O'Dell Group’s Atea Pharmaceuticals AVIR Stock Holding History

O'Dell Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-200
Closed -$610 – 122
2023
Q4 		$610 Buy
+200
New +$606 ﹤0.01% 472
2023
Q3 		– Sell
-200
Closed -$748 – 107
2023
Q2 		$748 Buy
+200
New +$749 ﹤0.01% 466
2022
Q4 		– Sell
-200
Closed -$1K – 100
2022
Q3 		$1K Hold
200
– – ﹤0.01% 390
2022
Q2 		$1K Hold
200
– – ﹤0.01% 427
2022
Q1 		$1K Hold
200
– – ﹤0.01% 468
2021
Q4 		$2K Hold
200
– – ﹤0.01% 444
2021
Q3 		$7K Buy
+200
New +$5.55K ﹤0.01% 330

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

O'Dell Group's AVIR Position: Q1 2024 in Review

O'Dell Group sold out of Atea Pharmaceuticals (AVIR) in Q1 2024, closing a stake of 200 shares — an estimated $610 sold.

O'Dell Group first reported a position in AVIR in Q3 2021 and held it in 7 quarters. The position peaked at $7K in Q3 2021. 113 funds tracked by Wall St. Rank hold AVIR as of Q1 2024.

  • O'Dell Group reported no remaining Atea Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • O'Dell Group sold 200 Atea Pharmaceuticals shares in Q1 2024, an estimated $610.
  • O'Dell Group first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • O'Dell Group's Atea Pharmaceuticals position peaked at $7K in Q3 2021.
  • 113 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2024.

Based on O'Dell Group's 13F filing for Q1 2024, filed 7 May 2024.